[Effectiveness of riamilovir in preventing respiratory viral infection among young people from organized collectives].

IF 0.3 4区医学 Q3 MEDICINE, GENERAL & INTERNAL

Terapevticheskii Arkhiv Pub Date : 2024-12-16 DOI:10.26442/00403660.2024.11.203024

K V Kozlov, O V Maltsev, K V Kasyanenko, V S Sukachev, A V Saulevich, S S Karyakin, A D Dubrovin, R N Smirnov

{"title":"[Effectiveness of riamilovir in preventing respiratory viral infection among young people from organized collectives].","authors":"K V Kozlov, O V Maltsev, K V Kasyanenko, V S Sukachev, A V Saulevich, S S Karyakin, A D Dubrovin, R N Smirnov","doi":"10.26442/00403660.2024.11.203024","DOIUrl":null,"url":null,"abstract":"Aim: To evaluate the efficacy of the antiviral drug riamilovir (trade name - «Triazavirin®») for the prevention of SARS-CoV-2 infection (COVID-19) and other acute respiratory viral infections in young people from organized groups.Materials and methods: The study involved 386 individuals aged 18-22 years: 199 received riamilovir at a daily dose of 250 mg for 15 days, while 187 did not receive prophylactic drugs. For 30 days, disease occurrence was monitored among volunteers. In case of illness, the duration, severity of clinical manifestations, complications, and pathogen elimination dynamics were assessed via PCR from nasopharyngeal and oropharyngeal swabs.Results: During riamilovir administration, a statistically significant reduction in cases of acute respiratory viral infections of non-coronavirus etiology was observed, with no COVID-19 cases reported, confirmed by the absence of SARS-CoV-2 RNA in this group. The shortest duration of acute respiratory viral infections was noted in patients taking the prophylactic drug.Conclusion: Riamilovir (trade name - «Triazavirin®») showed statistically significant prophylactic efficacy during its administration in an organized group. Its use decreased the frequency of detection of viral pathogens and resulted in milder acute respiratory disease, likely due to reduced viral load in individuals.","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"96 11","pages":"1035-1041"},"PeriodicalIF":0.3000,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Terapevticheskii Arkhiv","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.26442/00403660.2024.11.203024","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To evaluate the efficacy of the antiviral drug riamilovir (trade name - «Triazavirin^®») for the prevention of SARS-CoV-2 infection (COVID-19) and other acute respiratory viral infections in young people from organized groups.

Materials and methods: The study involved 386 individuals aged 18-22 years: 199 received riamilovir at a daily dose of 250 mg for 15 days, while 187 did not receive prophylactic drugs. For 30 days, disease occurrence was monitored among volunteers. In case of illness, the duration, severity of clinical manifestations, complications, and pathogen elimination dynamics were assessed via PCR from nasopharyngeal and oropharyngeal swabs.

Results: During riamilovir administration, a statistically significant reduction in cases of acute respiratory viral infections of non-coronavirus etiology was observed, with no COVID-19 cases reported, confirmed by the absence of SARS-CoV-2 RNA in this group. The shortest duration of acute respiratory viral infections was noted in patients taking the prophylactic drug.

Conclusion: Riamilovir (trade name - «Triazavirin^®») showed statistically significant prophylactic efficacy during its administration in an organized group. Its use decreased the frequency of detection of viral pathogens and resulted in milder acute respiratory disease, likely due to reduced viral load in individuals.

查看原文本刊更多论文

[利米洛韦预防有组织集体青少年呼吸道病毒感染的有效性]。

目的：评价抗病毒药物利亚米洛韦（商品名：“Triazavirin®”）在有组织人群中预防青年人感染SARS-CoV-2 （COVID-19）及其他急性呼吸道病毒感染的疗效。材料和方法：研究对象为386名年龄在18-22岁之间的个体，其中199人每天服用250毫克利米洛韦，持续15天，187人未服用预防药物。在30天的时间里，监测志愿者的疾病发生情况。在患病的情况下，通过鼻咽和口咽拭子PCR评估病程、临床表现严重程度、并发症和病原体消除动态。结果：利米洛韦给药期间，非冠状病毒引起的急性呼吸道病毒感染病例有统计学意义的减少，无COVID-19病例报告，证实了该组中没有SARS-CoV-2 RNA。服用预防性药物的患者急性呼吸道病毒感染持续时间最短。结论：Riamilovir（商品名- Triazavirin®）在给药期间具有统计学上显著的预防效果。它的使用减少了病毒病原体的检测频率，并导致较轻的急性呼吸道疾病，可能是由于个体的病毒载量减少。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Terapevticheskii Arkhiv 医学-医学：内科

CiteScore

1.40

自引率

33.30%

发文量

171

审稿时长

3-8 weeks

期刊介绍： Терапевтический архив The journal was founded by the prominent Russian therapists M.P. Konchalovsky and G.F. Lang in 1923. Then its editors-in-chief were Professors V.N. Vinogradov and A.G. Gukasyan. Since 1972, E.I. Chazov, Academician of the Russian Academy of Sciences, has been heading the editorial board of the journal. Over 90 years, there have been more than 1000 issues where the authors and editorial staff have done their best for readers to keep abreast of current advances in medical science and practice and for physicians to master the advanced principles of recognition and treatment of a wide spectrum of visceral diseases. The papers published in the journal (editorials, original articles, lectures, reviews, etc.) cover both current scientific achievements and practical experience in diagnosing, treating, and preventing visceral diseases. The authors of publications are not only Russian, but also foreign scientists and physicians. All papers are peer-reviewed by highly qualified Russian specialists. The journal is published monthly. Traditionally, each issue has predominantly certain thematic areas covering individual therapy specializations. Every year, one of the issues is devoted to related problems in practical medicine (allergology and immunology, neurology and psychiatry, obstetrics, oncology, etc.). This all draws the attention of the reading public to the journal. The journal is indexed in RSCI (Russian Science Citation Index), PubMed/Medline, Index Medicus, Scopus/EMBASE, Web of Science Core Collection (Science Citation Index Expanded), Web of Science (Russian Science Citation Index - RSCI, Current Contents Connect, BIOSIS Previews), Google Scholar, Ulrich''s Periodicals Directory. The journal is included in the list of periodicals recommended by the Higher Attestation Committee for publishing the papers containing the basic materials of doctoral and candidate dissertations. By the decision of the Presidium of the Russian Academy of Medical Sciences, the “Therapevticheskiy Arkhiv” was awarded the Botkin medal. It was admitted to the European Association of Sciences Editors (EASE). The journal was honored with the Golden Press Fund decoration at the 13th International Press Professional Exhibition.